GLP-3 Retatrutide Research
Retatrutide Clinical Trials Overview – Evidence Snapshot
Summarized from publicly available study reports and registries. Always refer to the original publications and regulatory documents.
Obesity & Weight Management Studies
Key Signals from Phase 2 Obesity Trials
- In the Phase 2 obesity trial reported in the New England Journal of Medicine (2023), once-weekly dosing in adults with obesity was associated with substantial, dose-dependent weight reduction under trial conditions — a mean of 24.2% at the 12 mg dose over 48 weeks. These are trial-reported outcomes, not results offered by this site.
- Higher-dose arms reported weight-loss percentages that approach or exceed those reported for leading approved incretin-based therapies in similar time frames.
- Improvement in cardiometabolic markers was observed as an exploratory trial outcome.
Retatrutide remains an investigational compound and is not approved by the FDA for any use.
Type 2 Diabetes & Metabolic Trials
- Studies in type 2 diabetes populations show meaningful HbA1c reductions and weight loss compared with placebo and active comparators.
- Ongoing programs continue to evaluate durability, body composition, liver fat, and cardiovascular endpoints.
How GLP3 Weight Loss Uses This Data
Our role is to interpret these findings in a measured, regulatory-aware way: highlighting mechanisms and trends without marketing non-approved use.
For risk considerations, visit Retatrutide Safety & Risks.